Clinical Trial

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Exploring the therapeutic effect of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab on advanced stage III-IV endometrial cancer
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-12-01 -> 2027-12-01 2026-07-29
minor Completion pushed: 2031-12-01 -> 2032-12-01 2026-07-29
Trial Details
NCT Number NCT06561308
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Collaborators: Xiangya Hospital of Central South University, Tongji Hospital, Qilu Hospital of Shandong University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Henan Provincial People's Hospital, Hunan Cancer Hospital, Zhejiang Cancer Hospital, First Affiliated Hospital of Wenzhou Medical University, Ningbo No. 1 Hospital, The First Affiliated Hospital of Zhengzhou University, Tianjin Medical University General Hospital
Conditions Endometrioid Endometrial Cancer
Enrollment 39 participants
Start Date 2025-09-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2032-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-29